KIT and cancer: When an activating KIT mutation is observed in TET, KIT inhibitors such as imatinib, sunitinib, or sorafenib, based on the sensitivity to these inhibitors reported in other cancers, like gastro-intestinal stromal tumors, may be considered [53, 54].